ZIDOVUDINE

Post-LOE

zidovudine

Aurobindo Pharma

ANDAORALSOLUTION

Approved

Sep 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Aurobindo Pharma is nucleoside reverse transcriptase inhibitors [moa]. Approved for maternal-fetal hiv-1 transmission [see ], combination with other antiretroviral agents for the treatment of hiv-1 infection. First approved in 2005.

Drug data last refreshed 19h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection

Clinical Trials (20)

NCT00001025Phase 2Completed

Evaluation of Patients Who Have Not Had Success With Zidovudine

120 enrolled

HIV Infections

NCT00000999Phase 1Completed

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

500 enrolled

HIV Infections

NCT00270010Phase 2Completed

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease

72 enrolled

AnemiaAcquired Immunodeficiency Syndrome

NCT00270270Phase 2Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy

63 enrolled

Acquired Immunodeficiency SyndromeAnemia

NCT00000672Phase 2Completed

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

660 enrolled

HIV Infections

Worked on ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.